Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and PK/PD of Multiple Rising Doses of Opicapone in Healthy Men
NCT02071810Phase 1Completed
- Sponsor
- BIAL
- Start
- Apr 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of opicapone in Parkinson's disease (PD) (5 arms), sponsored by BIAL. Primary endpoint: Number of Patients With at Least One Adverse Event at 6 weeks. Started Apr 2008; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02071810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071810.